diseases, of which cyclooxygenase (COX), and homocysteine can be indicated. COX-derived prostaglandins contribute to various cellular biological functions and influence both diseases. However, the net effect and the role of each of COX-1 or COX-2 is not completely understood. In this regard, and according to the different controversial effects observed from nonsteroidal anti-inflammatory drugs, the issue needs more investigations [12] . In addition, the effect of n-3 fatty acids on bone density as well as atherosclerosis originates from its effect on COX enzyme is interesting. Our study on postmenopausal women showed a negative effect of n-3 fatty acids on a bone resorption marker (pyridinoline) [13, 14] .
Furthermore, there is a strong link between hyperhomocysteinaemia, osteoporosis and CVD, which needs to be investigated in detail [15] . The link between cholesterol biosynthesis and bone metabolism was proposed and confirmed in several studies, and also it was revealed that statins affect bone density, although the therapeutic pathway which affects both is not obvious [7] . In addition to the above-mentioned pathways, the role of the sympathetic nervous system in bone metabolism should be considered [16] .
Supporting above-mentioned findings, a positive correlation was found between bone mineral density and total body fat, and with abdominal fat [17] . Also it has been shown that children with juvenile rheumatoid arthritis have lower BMD and higher serum OPG and RANKL [18] .
Taken together, we have a long way into surveying the strong link between osteoporosis and CVD, and it is far more than finding one or two biomarkers. In fact, both diseases should be viewed as one complex senile disease which several risk factors and pathogenesis affects it.
Furthermore, an interesting new issue in the treatment of osteoporosis is the adverse effect of calcium supplementation on the cardiovascular system, which is a new, challenging issue and will be discussed in detail in our next paper.
